Htr6 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Protein Name | Serotonin Receptor 6 |
| Gene Symbol | htr6 |
| UniProt ID | P50406 |
| Molecular Weight | ~45-50 kDa |
| Subcellular Localization | Plasma membrane, dendrites |
| Protein Family | 5-HT6 family (GPCR) |
| Signal Transduction | Gs protein-coupled, stimulates adenylate cyclase |
The Serotonin Receptor 6 (HTR6) is a Gs-coupled GPCR encoded by the HTR6 gene. It is almost exclusively expressed in the brain, particularly in areas important for cognition and emotion (olfactory tubercle, nucleus accumbens, striatum, hippocampus). HTR6 has attracted interest as a cognitive enhancement target.
HTR6 has a typical GPCR structure with unique features:
Unlike most 5-HT receptors, HTR6 exclusively couples to Gs proteins, making it unique in the 5-HT receptor family.
HTR6 mediates important brain functions:
HTR6 is highly expressed in brain regions affected by AD (hippocampus, cortex). HTR6 antagonists (e.g., idalopirdine) have been investigated as cognitive enhancers, though clinical trials showed mixed results. The receptor may modulate cholinergic signaling relevant to AD.
HTR6 in the basal ganglia influences motor control and may be affected in PD. Novel HTR6 modulators are being explored for PD cognitive symptoms.
HTR6 antagonists show antidepressant-like effects in animal models. Combined serotonin reuptake inhibition with HTR6 antagonism may offer enhanced therapeutic benefit.
HTR6 is a potential target for treating cognitive deficits in schizophrenia. Atypical antipsychotics with HTR6 antagonist activity may provide cognitive benefits.
| Drug Class | Examples | Mechanism | Status |
|---|---|---|---|
| Antagonists | Idalopirdine, SB-742457 | Block receptor signaling | Research/Clinical trials |
| Inverse Agonists | Antagonists with negative efficacy | Inhibit constitutive activity | Research |
| Antidepressant Augmentation | Combined SSRIs + HTR6 antagonists | Enhanced efficacy | Research |
The study of Htr6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Monsma FJ, et al. (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molecular Pharmacology. PMID:8101448
[2] Woolley ML, et al. (2004). 5-HT6 receptors as a target for cognition enhancement. CNS Drug Reviews. PMID:15592523
[3] Upton N, et al. (2008). 5-HT6 receptor antagonists as novel cognitive enhancing agents. Expert Opinion on Therapeutic Patents. PMID:18616487
[4] Ramirez MJ, et al. (2014). 5-HT6 receptor and cognition. Behavioural Brain Research. PMID:24583232
[5] Huang M, et al. (2017). 5-HT6 receptor and antipsychotic drug action. Current Neuropharmacology. PMID:28412922